Finland· FI-REL-REL12396
Visudyne
A verteporfin product containing verteporfin, registered in Finland by Cheplapharm Arzneimittel GmbH. The same ATC class is registered in 15 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Verteporfin is registered in 15 of 19 countries.
Countries holding a registration under ATC S01LA01 (verteporfin), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 9 of them publish a price we can compare per daily dose
Verteporfin · ATC S01LA01
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Verteporfin
- Manufacturer
- Cheplapharm Arzneimittel GmbH
- Country
- Finland (FI)
- ATC code
- S01LA01
- ATC class
- Verteporfin
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 1
1 priced- fi_myyntilupa00261615 mgEUR 2223.6
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
166 interactions on record for verteporfin.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Verteporfin · interactions on record
166 records
- 1 severe
- 144 moderate
- 2 minor
- 19 info
Most severe, free to view
- Aminolevulinic acidL01XD04severe
- TetracyclineA01AB13moderate
- DoxycyclineA01AB22moderate
- MinocyclineA01AB23moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Verteporfin in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayVisudyneCheplapharm Arzneimittel GmbH
- United KingdomVerteporfin 15mg powder for solution for infusion vialsNeon Healthcare Ltd
- IrelandVisudyne 15 mg powder for solution for infusionCHEPLAPHARM Arzneimittel GmbH
- IcelandVisudyneCHEPLAPHARM Arzneimittel GmbH
- PolandVisudyneCHEPLAPHARM Arzneimittel GmbH
- BelgiumVisudyne 15 mgCheplapharm Arzneimittel
- SwedenVisudyne 15 mg Pulver till infusionsvätska, lösningCheplapharm Arzneimittel GmbH
- CzechiaVISUDYNECHEPLAPHARM Arzneimittel GmbH, Greifswald
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Visudyne
- Liechtenstein · Visudyne
- Norway · Visudyne
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c61ab046-fe8b-4c63-afd8-27b9bcd888e1 GET /v1/drugs/c61ab046-fe8b-4c63-afd8-27b9bcd888e1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "infuusiokuiva-aine, liuosta varten",
"route": "Laskimoon",
"ddd_unit": null,
"strength": "15 mg",
"atc_label": "verteporfiini",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/00/140/001",
"fimea_rel_id": "REL12396",
"authorised_at": "2000-07-27"
}See everything about verteporfin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.